The highly anticipated 6th Complement-based Drug Development Summit returns as the only industry forum dedicated to maximizing the therapeutic and commercial opportunity of next-generation targeted complement approaches in the pan-disease setting.
Join your peers to discuss the intricacies of complement signaling, promising complement targets beyond C3 and C5, translating preclinical research into phase 1a/b investigations, de-risking complement drugs in early trials for both chronic and rare/acute diseases, as well as validating biomarkers of complement activation.
Leverage key learnings and insights with 28+ expert speakers, a content packed two-tracked agenda, a pre-conference workshop on complement in the neuro setting, and new content on the hottest areas of complement R&D.
As the growth potential of emerging complement-targeted therapeutics becomes a reality, this year’s meeting will be your most comprehensive guide for addressing the unique challenges of complement-based drug development.
